1. Home
  2. SRPT vs CHE Comparison

SRPT vs CHE Comparison

Compare SRPT & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRPT
  • CHE
  • Stock Information
  • Founded
  • SRPT 1980
  • CHE 1970
  • Country
  • SRPT United States
  • CHE United States
  • Employees
  • SRPT N/A
  • CHE N/A
  • Industry
  • SRPT Biotechnology: Pharmaceutical Preparations
  • CHE Medical/Nursing Services
  • Sector
  • SRPT Health Care
  • CHE Health Care
  • Exchange
  • SRPT Nasdaq
  • CHE Nasdaq
  • Market Cap
  • SRPT N/A
  • CHE 8.8B
  • IPO Year
  • SRPT 1997
  • CHE N/A
  • Fundamental
  • Price
  • SRPT $36.52
  • CHE $569.11
  • Analyst Decision
  • SRPT Buy
  • CHE Buy
  • Analyst Count
  • SRPT 23
  • CHE 1
  • Target Price
  • SRPT $131.09
  • CHE $674.00
  • AVG Volume (30 Days)
  • SRPT 3.8M
  • CHE 129.5K
  • Earning Date
  • SRPT 05-06-2025
  • CHE 04-23-2025
  • Dividend Yield
  • SRPT N/A
  • CHE 0.35%
  • EPS Growth
  • SRPT N/A
  • CHE 10.48
  • EPS
  • SRPT N/A
  • CHE 20.53
  • Revenue
  • SRPT $2,233,371,000.00
  • CHE $2,488,997,000.00
  • Revenue This Year
  • SRPT $64.51
  • CHE $9.04
  • Revenue Next Year
  • SRPT $22.40
  • CHE $6.68
  • P/E Ratio
  • SRPT N/A
  • CHE $28.09
  • Revenue Growth
  • SRPT 59.15
  • CHE 8.52
  • 52 Week Low
  • SRPT $35.46
  • CHE $512.12
  • 52 Week High
  • SRPT $173.25
  • CHE $623.61
  • Technical
  • Relative Strength Index (RSI)
  • SRPT 22.82
  • CHE 44.77
  • Support Level
  • SRPT $59.62
  • CHE $568.44
  • Resistance Level
  • SRPT $64.80
  • CHE $583.37
  • Average True Range (ATR)
  • SRPT 3.75
  • CHE 15.09
  • MACD
  • SRPT -1.21
  • CHE 0.45
  • Stochastic Oscillator
  • SRPT 3.61
  • CHE 56.35

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

About CHE Chemed Corp

Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.

Share on Social Networks: